Adaptive Biotechnologies Corporation
DE ˙ MUN ˙ US00650F1093
13,58 € ↑0,76 (5,89%)
2026-06-04
CENA AKCJI
SecurityDE:1HM / Adaptive Biotechnologies Corporation
InstitutionSei Investments Co
Latest Disclosed Ownership316,569 shares
Latest Disclosed Value $ 5,141,083
Sei Investments Co reports 164.42% increase in ownership of 1HM / Adaptive Biotechnologies Corporation

On February 13, 2026 - Sei Investments Co filed a 13F-HR form disclosing ownership of 316,569 shares of Adaptive Biotechnologies Corporation (DE:1HM) valued at $4,406,640 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 119,723 shares of Adaptive Biotechnologies Corporation. This represents a change in shares of 164.42% during the quarter. The current value of the position is $4,299,007 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 316,569 196,846 164.42 5,141 187.05
2025-11-13 2025-09-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 119,723 -27,169 -18.50 1,791 4.68 0.0019
2025-08-14 2025-06-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 146,892 128,453 696.64 1,711 1,158.09 0.0020
2025-05-14 2025-03-31 13F/A-1 ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 18,439 2,995 19.39 137 47.83 0.0002
2025-05-13 2025-03-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 15,444 0 93 0.0001
2025-02-11 2024-12-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 15,444 19 0.12 93 17.95 0.0001
2024-11-12 2024-09-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 15,425 69 0.45 79 41.82 0.0001
2024-08-13 2024-06-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 15,356 -49,461 -76.31 56 -73.56 0.0001
2024-05-07 2024-03-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 64,817 37 0.06 208 -34.38 0.0003
2024-02-14 2023-12-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 64,780 220 0.34 317 -9.69 0.0005
2023-11-14 2023-09-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 64,560 20,152 45.38 352 18.18 0.0006
2023-08-11 2023-06-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 44,408 -2,453 -5.23 298 -28.09 0.0005
2023-05-12 2023-03-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 46,861 25,591 120.31 414 154.94 0.0008
2023-02-10 2022-12-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 21,270 2,078 10.83 163 18.25 0.0004
2022-11-14 2022-09-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 19,192 -2,223 -10.38 137 -20.81 0.0003
2022-08-15 2022-06-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 21,415 -48,233 -69.25 173 -82.11 0.0004
2022-05-13 2022-03-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 69,648 641 0.93 967 -50.05 0.0019
2022-02-14 2021-12-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 69,007 4,396 6.80 1,936 -11.84 0.0036
2021-11-12 2021-09-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 64,611 -1,874 -2.82 2,196 -19.15 0.0046
2021-08-06 2021-06-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 66,485 -18,190 -21.48 2,716 -28.47 0.0060
2021-05-12 2021-03-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 84,675 -50,272 -37.25 3,797 -52.32 0.0096
2021-02-08 2020-12-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 134,947 15,216 12.71 7,964 36.53 0.0206
2020-12-04 2020-09-30 13F/A-1 ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 119,731 5,941 5.22 5,833 5.96 0.0169
2020-11-06 2020-09-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 132,759 18,969 6,467 15,571.0981
2020-08-17 2020-06-30 13F/A-1 ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 113,790 -5,172 -4.35 5,505 66.57 0.0171
2020-08-11 2020-06-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 56,485 -62,477 1,696 4,600.4903
2020-05-14 2020-03-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 118,962 62,815 111.88 3,305 96.73 0.0121
2020-02-06 2019-12-31 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 56,147 27,647 97.01 1,680 90.69 0.0050
2019-11-12 2019-09-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 28,500 13,189 86.14 881 19.05 0.0023
2019-08-14 2019-06-30 13F ADAPTIVE BIOTECHNOLOGIES COR COM 00650F109 15,311 15,311 740 0.0024
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.